Control Of Diabetes And Obesity
AssigneeUniversity of Southern California
InventorAmy Lee
Life of this patent
Estimating the term…
Abstract
Provided are methods of increasing resistance to and methods of treating disorders associated with weight gain. Also provided are methods of screening for an agent that prevents or treats a disorder associated with weight gain using animal models heterozygous for IP3R1.
Claims25
A method of increasing resistance to a disorder associated with weight gain in a subject comprising:
- a) selecting a subject at risk for developing a disorder associated with weight gain;
- and
- b) administering to the subject one or more agents that inhibit expression or activity of GRP78.
A method of treating a disorder associated with weight gain in a subject comprising:
- a) selecting a subject that has a disorder associated with weight gain;
- and
- b) administering to the subject one or more agents that inhibit expression or activity of GRP78.
A method of increasing resistance to a disorder associated with weight gain in a subject comprising:
- a) selecting a subject at risk for developing a disorder associated with weight gain;
- and
- b) administering to the subject one or more IP3R1 agonists.
A method of treating a disorder associated with weight gain in a subject comprising:
- a) selecting a subject that has a disorder associated with weight gain;
- and
- b) administering to the subject one or more IP3R1 agonists.
A non-human animal comprising a disruption in an endogenous GRP78 gene such that the GRP78 gene is non-functional or does not express a functional GRP78 protein.
A non-human animal comprising a disruption in an endogenous IP3R1 gene such that the IP3R1 gene is non-functional or does not express a functional IP3R1 protein, wherein the disruption is an insertion of a transgene into the endogenous IP3R1 gene.
A method of screening for an agent that prevents or treats a disorder associated with weight gain, comprising:
- a) administering an agent to be tested to the non-human animal of claim 34;
- and
- b) detecting fasting insulin level in the non-human animal, wherein an increase in fasting insulin levels indicates the agent prevents or treats a disorder associated with weight gain.
Dependencies are inferred from the claim text.